Bicycle Therapeutics plc (BCYC)Healthcare | Biotechnology | Cambridge, United Kingdom | NasdaqGS
4.35 USD
-0.06
(-1.361%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 4.35 |
Hot Take ↕ | July 11, 2026, 5:46 a.m. EDT
The investment case here is severely compromised by deteriorating fundamentals and aggressive insider selling. The company is hemorrhaging cash with negative free cash flow and a massive operating burn, while revenue has collapsed by nearly 91% year-over-year. This is compounded by a toxic insider environment where the CFO, COO, and CEO have recently executed significant sell-to-cover transactions, signaling a lack of confidence in the near-term outlook. While the stock trades at a discount to book value, this appears to be a value trap driven by the company's inability to generate revenue or profits. The price action reflects this distress, having lost significant ground over the last few months. With no dividend to provide income and a balance sheet that is burning through its cash reserves, the long-term outlook is bleak. The short-term view remains bearish due to the weight of the insider selling pressure and the structural decline in business performance. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.104264 |
| MSTL_105 | 0.116611 |
| AutoETS | 0.127519 |
| AutoARIMA | 0.128041 |
| MSTL | 0.134459 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 15.02 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.291 |
| Excess Kurtosis | -0.83 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.767 |
| Revenue per Share | 0.915 |
| Market Cap | 303,678,816 |
| Forward P/E | -2.05 |
| Beta | 1.55 |
| Website | https://www.bicycletherapeutics.com |
As of July 11, 2026, 5:46 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest is massive relative to calls, particularly at strikes below the current price (e.g., 3.0 and 4.0), indicating a heavy hedge against further declines. Call activity is sparse and concentrated at out-of-the-money strikes, suggesting limited speculative appetite for a rally despite the low implied volatility.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.4542079 |
| Address1 | Portway Building |
| Address2 | Blocks A & B Granta Park Great Abington |
| All Time High | 62.075 |
| All Time Low | 3.92 |
| Ask | 5.41 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 519,100 |
| Average Daily Volume3 Month | 464,685 |
| Average Volume | 464,685 |
| Average Volume10Days | 519,100 |
| Beta | 1.55 |
| Bid | 3.13 |
| Bid Size | 2 |
| Book Value | 7.952 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.35 |
| Current Ratio | 12.664 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 4.37 |
| Day Low | 4.16 |
| Debt To Equity | 2.767 |
| Display Name | Bicycle Therapeutics |
| Earnings Timestamp | 1,777,552,200 |
| Earnings Timestamp End | 1,777,552,200 |
| Earnings Timestamp Start | 1,777,552,200 |
| Ebitda | -232,226,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 1.035 |
| Enterprise To Revenue | -3.787 |
| Enterprise Value | -240,458,176 |
| Eps Current Year | -2.275 |
| Eps Forward | -2.12556 |
| Eps Trailing Twelve Months | -3.15 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.3924 |
| Fifty Day Average Change | -0.042399883 |
| Fifty Day Average Change Percent | -0.009653011 |
| Fifty Two Week Change Percent | -45.42079 |
| Fifty Two Week High | 9.183 |
| Fifty Two Week High Change | -4.8329997 |
| Fifty Two Week High Change Percent | -0.5262986 |
| Fifty Two Week Low | 3.92 |
| Fifty Two Week Low Change | 0.42999983 |
| Fifty Two Week Low Change Percent | 0.10969383 |
| Fifty Two Week Range | 3.92 - 9.183 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,558,618,200,000 |
| Forward Eps | -2.12556 |
| Forward P E | -2.0465195 |
| Free Cashflow | -109,748,248 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 288 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -2.4454 |
| Gross Profits | -155,272,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04487 |
| Held Percent Institutions | 0.73815 |
| Implied Shares Outstanding | 69,811,225 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. |
| Long Name | Bicycle Therapeutics plc |
| Market | us_market |
| Market Cap | 303,678,816 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_72510621 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -219,031,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 307,867,502 |
| Number Of Analyst Opinions | 8 |
| Open | 4.37 |
| Operating Cashflow | -229,230,000 |
| Operating Margins | -73.82413 |
| Payout Ratio | 0.0 |
| Phone | 44 1223 261 503 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 4.35 |
| Post Market Time | 1,783,973,404 |
| Previous Close | 4.41 |
| Price Eps Current Year | -1.9120878 |
| Price Hint | 4 |
| Price To Book | 0.5470322 |
| Price To Sales Trailing12 Months | 4.7826447 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.281 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0599999 |
| Regular Market Change Percent | -1.36054 |
| Regular Market Day High | 4.37 |
| Regular Market Day Low | 4.16 |
| Regular Market Day Range | 4.16 - 4.37 |
| Regular Market Open | 4.37 |
| Regular Market Previous Close | 4.41 |
| Regular Market Price | 4.35 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 297,183 |
| Return On Assets | -0.19376 |
| Return On Equity | -0.33835998 |
| Revenue Growth | -0.911 |
| Revenue Per Share | 0.915 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 50,373,281 |
| Shares Percent Shares Out | 0.041300002 |
| Shares Short | 2,883,802 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 2,861,415 |
| Short Name | Bicycle Therapeutics plc |
| Short Percent Of Float | 0.074200004 |
| Short Ratio | 4.49 |
| Source Interval | 15 |
| Symbol | BCYC |
| Target High Price | 36.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 12.625 |
| Target Median Price | 10.0 |
| Total Cash | 559,473,984 |
| Total Cash Per Share | 8.014 |
| Total Debt | 15,337,000 |
| Total Revenue | 63,496,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.15 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.8991 |
| Two Hundred Day Average Change | -1.5490999 |
| Two Hundred Day Average Change Percent | -0.26259938 |
| Type Disp | Equity |
| Volume | 297,183 |
| Website | https://www.bicycletherapeutics.com |
| Zip | CB21 6GS |